HOXA10 and hepatocellular carcinoma: Additionally, miR-135a targets HOXA10, a key modulator of the MAPK/ERK pathway, and its downregulation in HBV-positive HCC leads to increased HOXA10 expression, which drives cell proliferation through the MAPK pathway (7).